Alexander A. Tsynchenko
Alexander A. Tsynchenko has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Alexey Yurievich Polushin
Pavlov First Saint Petersburg State Medical University
6 shared publications - Yu. R. Zalyalov
Pavlov University
5 shared publications Ю. Р. Залялов
Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова
5 shared publications- Aleksander Dmitrievich Kulagin
Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
4 shared publications - Iaroslav B. Skiba
Pavlov First Saint Petersburg State Medical University
4 shared publications E. I. Lopatina
Pavlov University
3 shared publications
Latest Publications
- Open Access
- 11 October 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 2,p. 88-91
Predictors of cardiomyopathy development in patients undergoing high-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation
Predictors of cardiomyopathy development in patients undergoing high-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation | Shurakova | New St. Petersburg Medical Records Предикторы развития кардиомиопатии у пациентов при высокодозной иммуносупрессивной терапии и аутологичной трансплантации гемопоэтических стволовых клеток | Шуракова | Новые Санкт-Петербургские врачебные ведомости
- 11 October 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 2,p. 88-91
Open AccessPredictors of cardiomyopathy development in patients undergoing high-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation
Predictors of cardiomyopathy development in patients undergoing high-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation | Shurakova | New St. Petersburg Medical Records Предикторы развития кардиомиопатии у пациентов при высокодозной иммуносупрессивной терапии и аутологичной трансплантации гемопоэтических стволовых клеток | Шуракова | Новые Санкт-Петербургские врачебные ведомости
- Open Access
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Diagnostic Labyrinth of POEMS Syndrome: An Analysis of Real-World Clinical Practice
BACKGROUND. РOEMS syndrome is a rare multisystem syndrome associated with monoclonal proliferation of plasma cells or B-lymphocytes and based on cytokine-mediated pathogenetic mechanism. Despite the clear diagnostic criteria, timely verification of the diagnosis is challenging due to the extreme variability of clinical features. AIM. To study clinical and laboratory profile as well as diagnostic routes of patients with РOEMS syndrome. MATERIALS & METHODS. This retrospective observational study enrolled 40 patients with newly diagnosed РOEMS syndrome treated at two major centers for hematology in the period from 01.2016 to 09.2025. RESULTS. On the date of POEMS syndrome diagnosis, the median age of patients was 58 years (range 28–80 years), and median time from symptom manifestation to diagnosis was 23 months (range 1–146 months). On initial presentation at the Federal center, 30 % of patients were severely disabled and completely immobilized. All of them met two essential criteria: polyneuropathy and monoclonal gammopathy. In the vast majority of cases, polyneuropathy manifested itself in a sensory and motor form (87.5 %) with predominantly mixed axonal and demyelinating lesions (79.4 %). Paraprotein was identified in 97.5 % of patients, however in 30 % of them the pathologic clone of plasma cells was not detected by standard techniques. Other manifestations of POEMS syndrome include bone abnormalities (62.5 %), increased VEGF level (73 %), organomegaly (75 %), endocrinopathy (60 %), skin lesions (52.5 %), extravascular fluid overload (47.5 %), and thrombocytosis/polycythemia (45 %). Prior to diagnosis verification, on average, patients were examined by 3 (range 1–6) medical specialists, most often by a neurologist (62.5 %). At the diagnostic stage, chronic inflammatory demyelinating polyneuropathy (32.5 %) was widely and wrongly assumed. After examination by related specialists, 80 % of patients were referred to a hematologist. In 50 % of cases, lymphoproliferative diseases were identified, however, without verification of POEMS syndrome. In 20 % of patients, myeloproliferative neoplasia was wrongly diagnosed. CONCLUSION. For timely diagnosis of POEMS syndrome, medical specialists should raise awareness and alertness concerning its polymorphic clinical features and additionally strengthen interdisciplinary approaches.
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Open AccessDiagnostic Labyrinth of POEMS Syndrome: An Analysis of Real-World Clinical Practice
BACKGROUND. РOEMS syndrome is a rare multisystem syndrome associated with monoclonal proliferation of plasma cells or B-lymphocytes and based on cytokine-mediated pathogenetic mechanism. Despite the clear diagnostic criteria, timely verification of the diagnosis is challenging due to the extreme variability of clinical features. AIM. To study clinical and laboratory profile as well as diagnostic routes of patients with РOEMS syndrome. MATERIALS & METHODS. This retrospective observational study enrolled 40 patients with newly diagnosed РOEMS syndrome treated at two major centers for hematology in the period from 01.2016 to 09.2025. RESULTS. On the date of POEMS syndrome diagnosis, the median age of patients was 58 years (range 28–80 years), and median time from symptom manifestation to diagnosis was 23 months (range 1–146 months). On initial presentation at the Federal center, 30 % of patients were severely disabled and completely immobilized. All of them met two essential criteria: polyneuropathy and monoclonal gammopathy. In the vast majority of cases, polyneuropathy manifested itself in a sensory and motor form (87.5 %) with predominantly mixed axonal and demyelinating lesions (79.4 %). Paraprotein was identified in 97.5 % of patients, however in 30 % of them the pathologic clone of plasma cells was not detected by standard techniques. Other manifestations of POEMS syndrome include bone abnormalities (62.5 %), increased VEGF level (73 %), organomegaly (75 %), endocrinopathy (60 %), skin lesions (52.5 %), extravascular fluid overload (47.5 %), and thrombocytosis/polycythemia (45 %). Prior to diagnosis verification, on average, patients were examined by 3 (range 1–6) medical specialists, most often by a neurologist (62.5 %). At the diagnostic stage, chronic inflammatory demyelinating polyneuropathy (32.5 %) was widely and wrongly assumed. After examination by related specialists, 80 % of patients were referred to a hematologist. In 50 % of cases, lymphoproliferative diseases were identified, however, without verification of POEMS syndrome. In 20 % of patients, myeloproliferative neoplasia was wrongly diagnosed. CONCLUSION. For timely diagnosis of POEMS syndrome, medical specialists should raise awareness and alertness concerning its polymorphic clinical features and additionally strengthen interdisciplinary approaches.
- Open Access
- 9 April 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Regional blood circulation and microcirculation
- Vol. 24 (1) , 64-72
Cardiovascular system response to intravenous administration of physiologic sodium chloride solution in healthy subjects
Introduction. Infusion therapy, despite all its advantages, is not fully understood regarding its impact on the cardiovascular system when large volumes of fluid are used. Objective. To assess the response of the cardiovascular system to massive infusion load in 5 healthy individuals. Materials and Methods. The study included 5 healthy volunteers (2 men and 3 women), with a mean age of 31.6±5.3 years, mean weight of 73.25±15.8 kg, and mean body surface area of 1.83±0.2 m². The study protocol involved the administration of 0.9 % sodium chloride solution through a peripheral catheter for ≈10 hours during the daytime over 2 days, at a volume of 2.2 L/m² body surface area per day. Before the start of the experiment, as well as 48 hours (2 days) and 168 hours (7 days) after the start, all participants underwent measurements of body weight, blood pressure (BP), heart rate (HR), blood tests for NT-proBNP levels, and transthoracic echocardiography. Results. The study found no significant changes in BP, HR, and body weight. A significant increase in NT-proBNP level was noted, rising from 29.3±17.67 ng/ml to 295.4±136.1 ng/ml (p=0.018) after 48 hours of infusion, followed by a decrease (38.0±20.94 ng/ml, p=0.020) and normalization after 7 days. Additionally, after 48 hours, there was an increase in the volume of the left atrium (from 39.2±9.0 ml to 58.2±10.7 ml; p=0.003), basal size of the right ventricle (from 3.44±0.18 cm to 3.66±0.26 cm; p=0.020), and vertical size of the right atrium (from 4.12±0.24 cm to 4.56±0.37 cm; p=0.032), as well as an increase in the amplitude of tricuspid annulus systolic excursion (TAPSE) – from 2.5±0.27 cm to 2.94±0.25 cm; p=0.034) and the E/e’ index (from 3.87±0.52 to 4.83±0.35; p=0.015. Conclusion. Intravenous administration of large volumes of 0.9 %NaCL is associated with an enlargement of the right heart chambers, with enhanced contractility of the right ventricle, increased volume of the left atrium, elevated left ventricular filling pressure, and a marked increase in NT-proBNP. NT-proBNP level should be estimated outside of infusion therapy.
- 9 April 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Regional blood circulation and microcirculation
- Vol. 24 (1) , 64-72
Open AccessCardiovascular system response to intravenous administration of physiologic sodium chloride solution in healthy subjects
Introduction. Infusion therapy, despite all its advantages, is not fully understood regarding its impact on the cardiovascular system when large volumes of fluid are used. Objective. To assess the response of the cardiovascular system to massive infusion load in 5 healthy individuals. Materials and Methods. The study included 5 healthy volunteers (2 men and 3 women), with a mean age of 31.6±5.3 years, mean weight of 73.25±15.8 kg, and mean body surface area of 1.83±0.2 m². The study protocol involved the administration of 0.9 % sodium chloride solution through a peripheral catheter for ≈10 hours during the daytime over 2 days, at a volume of 2.2 L/m² body surface area per day. Before the start of the experiment, as well as 48 hours (2 days) and 168 hours (7 days) after the start, all participants underwent measurements of body weight, blood pressure (BP), heart rate (HR), blood tests for NT-proBNP levels, and transthoracic echocardiography. Results. The study found no significant changes in BP, HR, and body weight. A significant increase in NT-proBNP level was noted, rising from 29.3±17.67 ng/ml to 295.4±136.1 ng/ml (p=0.018) after 48 hours of infusion, followed by a decrease (38.0±20.94 ng/ml, p=0.020) and normalization after 7 days. Additionally, after 48 hours, there was an increase in the volume of the left atrium (from 39.2±9.0 ml to 58.2±10.7 ml; p=0.003), basal size of the right ventricle (from 3.44±0.18 cm to 3.66±0.26 cm; p=0.020), and vertical size of the right atrium (from 4.12±0.24 cm to 4.56±0.37 cm; p=0.032), as well as an increase in the amplitude of tricuspid annulus systolic excursion (TAPSE) – from 2.5±0.27 cm to 2.94±0.25 cm; p=0.034) and the E/e’ index (from 3.87±0.52 to 4.83±0.35; p=0.015. Conclusion. Intravenous administration of large volumes of 0.9 %NaCL is associated with an enlargement of the right heart chambers, with enhanced contractility of the right ventricle, increased volume of the left atrium, elevated left ventricular filling pressure, and a marked increase in NT-proBNP. NT-proBNP level should be estimated outside of infusion therapy.
- Open Access
- 19 February 2025
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
The successful treatment of refractory Crohn's disease by high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation: a clinical case
Despite the available novel drug treatments for inflammatory bowel diseases, the number of patients with treatment resistance has been growing. These patients might need more aggressive treatment strategies, as the lack of control over the persistent active inflammation results in the progression of Crohn's disease and development of complications. By now, two randomized controlled studies of high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT-AHSCT) for the treatment of refractory Crohn's disease (ASTIC and ASTIC-lite) have been completed: their results are quite equivocal. The paper presents the description of a clinical case illustrating the possibility of HDIT-AHSCT as an alternative strategy to achieve remission in a patient with refractory Crohn's disease. This was a young patient with a difficult-to-treat inflammatory Crohn's disease (terminal ileitis and colitis with perianal lesion – A2L3B1p) with high disease activity (frequent loose stools, severe fatigue, abdominal pain, weight loss; C-reactive protein 13 mg/l, erythrocyte sedimentation rate 40 mm/h, fecal calprotectin 1500 mcg/g, SES-CD 8 points). He underwent an HDIT-AHSCT procedure resulting in clinical, laboratory and endoscopic remission at 24 weeks. Up to 24 months, he did not require any resumption of the immunosuppressive and biological therapy. At present, the patient's follow up and monitoring is ongoing. Further accumulation of clinical data is needed for the evaluation of the efficacy and safety of HDIT-AHSCT, profiling of the patient candidates for the use of the procedure, choice of optimal conditioning regimens, time and algorithms of anti-relapse therapy.
- 19 February 2025
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
Open AccessThe successful treatment of refractory Crohn's disease by high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation: a clinical case
Despite the available novel drug treatments for inflammatory bowel diseases, the number of patients with treatment resistance has been growing. These patients might need more aggressive treatment strategies, as the lack of control over the persistent active inflammation results in the progression of Crohn's disease and development of complications. By now, two randomized controlled studies of high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT-AHSCT) for the treatment of refractory Crohn's disease (ASTIC and ASTIC-lite) have been completed: their results are quite equivocal. The paper presents the description of a clinical case illustrating the possibility of HDIT-AHSCT as an alternative strategy to achieve remission in a patient with refractory Crohn's disease. This was a young patient with a difficult-to-treat inflammatory Crohn's disease (terminal ileitis and colitis with perianal lesion – A2L3B1p) with high disease activity (frequent loose stools, severe fatigue, abdominal pain, weight loss; C-reactive protein 13 mg/l, erythrocyte sedimentation rate 40 mm/h, fecal calprotectin 1500 mcg/g, SES-CD 8 points). He underwent an HDIT-AHSCT procedure resulting in clinical, laboratory and endoscopic remission at 24 weeks. Up to 24 months, he did not require any resumption of the immunosuppressive and biological therapy. At present, the patient's follow up and monitoring is ongoing. Further accumulation of clinical data is needed for the evaluation of the efficacy and safety of HDIT-AHSCT, profiling of the patient candidates for the use of the procedure, choice of optimal conditioning regimens, time and algorithms of anti-relapse therapy.
- Open Access
- 3 November 2024
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 31 (2) , 44-55
Analysis of the quality of life in patients with multiple sclerosis within 3 years after high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation
Introduction. To date, data have been accumulated indicating the high effectiveness of the HDIT-AHSCT and the possibility of preserving and improving the quality of life of patients after its application.The objective was to analyze the dynamics of quality of life using standardized assessment tools in patients with MS for 3 years after the use of HDIT-AHSCT, who participated in the program of clinical approbation of the method.Methods and materials. The single-center observational study included 21 patients (10 women, 11 men) with a reliable diagnosis of MS, who underwent HDIT-AHSCT at the Pavlov First Saint Petersburg State Medical Universityin accordance with the protocol of clinical approbation. Distribution by type of MS course: remitting (RMS) 16 (76.2 %), secondary progressive (SPMS) 4 (19 %), primary progressive (PPMS) 1 patient (4.8 %). The assessment of quality of life (SF-36, FAMS, CSP-MS42, HADS) and severity of disability (EDSS) in all patients was performed before, 12 and 36 months after HDIT-AHSCT.Results. Three years after the HDIT-AHSCT, a significant decrease in weakness, feelings of constant fatigue and rapid fatigue during exertion was recorded. The level of anxiety decreased in more than 50 % of patients. A direct relationship between the dynamics of clinical characteristics and the data of the scales of the SF-36 questionnaire was revealed; at the same time, after 36 months, an improvement in all parameters of the scale was noted.Conclusion. The assessment of the indicators of the quality of life questionnaires allows us to confirm the effectiveness and significance of therapy not only from the point of view of objective clinical and radiation parameters necessary for the evidence base of the treatment method, but also from the patient’s position, which in conditions of a chronic progressive process is an integral factor for the appointment of therapeutic intervention.
- 3 November 2024
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 31 (2) , 44-55
Open AccessAnalysis of the quality of life in patients with multiple sclerosis within 3 years after high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation
Introduction. To date, data have been accumulated indicating the high effectiveness of the HDIT-AHSCT and the possibility of preserving and improving the quality of life of patients after its application.The objective was to analyze the dynamics of quality of life using standardized assessment tools in patients with MS for 3 years after the use of HDIT-AHSCT, who participated in the program of clinical approbation of the method.Methods and materials. The single-center observational study included 21 patients (10 women, 11 men) with a reliable diagnosis of MS, who underwent HDIT-AHSCT at the Pavlov First Saint Petersburg State Medical Universityin accordance with the protocol of clinical approbation. Distribution by type of MS course: remitting (RMS) 16 (76.2 %), secondary progressive (SPMS) 4 (19 %), primary progressive (PPMS) 1 patient (4.8 %). The assessment of quality of life (SF-36, FAMS, CSP-MS42, HADS) and severity of disability (EDSS) in all patients was performed before, 12 and 36 months after HDIT-AHSCT.Results. Three years after the HDIT-AHSCT, a significant decrease in weakness, feelings of constant fatigue and rapid fatigue during exertion was recorded. The level of anxiety decreased in more than 50 % of patients. A direct relationship between the dynamics of clinical characteristics and the data of the scales of the SF-36 questionnaire was revealed; at the same time, after 36 months, an improvement in all parameters of the scale was noted.Conclusion. The assessment of the indicators of the quality of life questionnaires allows us to confirm the effectiveness and significance of therapy not only from the point of view of objective clinical and radiation parameters necessary for the evidence base of the treatment method, but also from the patient’s position, which in conditions of a chronic progressive process is an integral factor for the appointment of therapeutic intervention.
- Open Access
- 12 March 2024
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 29 (1) , 25-35
Quality of life of patients with multiple sclerosis after high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation
Introduction. Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disease of the central nervous system (CNS). High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT–AHSCT) is the most eff ective method of treating MS, which has a positive eff ect on the quality of life of patients and inhibition of the progression of disability.The aim of the study was to analyze the dynamics of quality of life in patients with MS who underwent the HDIT– AHSCT method in groups with diff erent clinical effi cacy of this method.Material and methods. The single-center observational study included patients with MS (n = 21, mean age 35.5 ± 6.2 (28–50) years; men/women — 11/10; remitting MS (RMS) n = 16, secondary-progressive (SPMS) n = 4, primaryprogressive (PPMS) n = 1), after HDIT–AHSCT (cyclophosphamide-rituximab conditioning regimen). Assessment of the quality of life (SF-36, FAMS, CSP-MS42, HADS) and the degree of disability in all patients was carried out before and 12 months after HDIT–AHSCT.Results. 12 months after HDIT–AHSCT, more than 50% of patients showed signifi cant improvement in quality of life according to the scales of viability and social functioning of the SF-36 questionnaire, as well as according to the scales of general well-being and additional problems of the FAMS questionnaire. 57% of patients had a signifi cant improvement in the overall FAMS score. According to the CSP-MS42 questionnaire, a decrease in weakness (p < 0.05), feelings of constant fatigue and rapid fatigue during exercise was revealed. After transplantation, there was a slight decrease in anxiety (p = 0.91) and a signifi cant decrease in depression (p = 0.011).Conclusion. The expected dynamics was established: in patients with clinical improvement, there was an improvement in the quality of life for most indicators; in patients with stabilization, most quality of life indicators were similar before and after HDIT–AHSCT; with clinical deterioration after HDIT–AHSCT, quality of life parameters worsened. These data indicate the expediency of further optimization of patient selection criteria and various stages of the HDIT–AHSCT in order to obtain optimal clinical results and, accordingly, improve the quality of life of patients.
- 12 March 2024
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 29 (1) , 25-35
Open AccessQuality of life of patients with multiple sclerosis after high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation
Introduction. Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disease of the central nervous system (CNS). High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT–AHSCT) is the most eff ective method of treating MS, which has a positive eff ect on the quality of life of patients and inhibition of the progression of disability.The aim of the study was to analyze the dynamics of quality of life in patients with MS who underwent the HDIT– AHSCT method in groups with diff erent clinical effi cacy of this method.Material and methods. The single-center observational study included patients with MS (n = 21, mean age 35.5 ± 6.2 (28–50) years; men/women — 11/10; remitting MS (RMS) n = 16, secondary-progressive (SPMS) n = 4, primaryprogressive (PPMS) n = 1), after HDIT–AHSCT (cyclophosphamide-rituximab conditioning regimen). Assessment of the quality of life (SF-36, FAMS, CSP-MS42, HADS) and the degree of disability in all patients was carried out before and 12 months after HDIT–AHSCT.Results. 12 months after HDIT–AHSCT, more than 50% of patients showed signifi cant improvement in quality of life according to the scales of viability and social functioning of the SF-36 questionnaire, as well as according to the scales of general well-being and additional problems of the FAMS questionnaire. 57% of patients had a signifi cant improvement in the overall FAMS score. According to the CSP-MS42 questionnaire, a decrease in weakness (p < 0.05), feelings of constant fatigue and rapid fatigue during exercise was revealed. After transplantation, there was a slight decrease in anxiety (p = 0.91) and a signifi cant decrease in depression (p = 0.011).Conclusion. The expected dynamics was established: in patients with clinical improvement, there was an improvement in the quality of life for most indicators; in patients with stabilization, most quality of life indicators were similar before and after HDIT–AHSCT; with clinical deterioration after HDIT–AHSCT, quality of life parameters worsened. These data indicate the expediency of further optimization of patient selection criteria and various stages of the HDIT–AHSCT in order to obtain optimal clinical results and, accordingly, improve the quality of life of patients.
- Open Access
- 23 November 2022
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 27 (5) , 25-35
High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: preliminary clinical results of approbation of the method
Introduction. In 2018–2020, a study was conducted in the Russian Federation on the efficacy and safety of highdose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT-AHSCT) in multiple sclerosis (MS).The aim of the study was to analyze preliminary data on the effectiveness and safety of the HDIT-AHSCT in patients with MS who participated in the clinical approbation of the method.Material and methods. 21 patients were included in a single-center Pavlov University (Saint Petersburg) observational study. In 10 patients (47.6%) the Expanded Disability Status Scale (EDSS) ranged from 1.0 to 4.0, in 10 — from 4.5 to 6.0 points, 1 patient with primary-progressive MS (PPMS) had 6.5 EDSS points. Cyclophosphamide conditioning regimen (200 mg/kg) in combination with rituximab (1000 mg/m2) was used. Neurological assessment (EDSS, SNRS, T25-FW, 9-HPT, PASAT, MoCA, HADS) and brain MRI were performed before and after 12 months. The early and long-term complications of HDIT-AHSCT were also analyzed.Results. One year after HDIT-AHSCT improvement and significant improvement were noted in 10 patients (47.6%), stabilization — in 8 (38.1%), relapse/progression — in 3 (14.3%). A lower effect was observed in patients with spasticity of more than 3 points by the MAS. According to MRI data 18 patients (85.7%) had stabilization of MS with no disease activity after 1 year, that met the No Evidence of Disease Activity (NEDA) criteria. Long-term complications included autoimmune thyroiditis (n = 1) and amenorrhea in two patients older than 38 years. No TRM were registered during the observation period.Conclusion. HDIT-AHSCT is an effective method of treating patients with multiple sclerosis. The results of the research demonstrate the safety and effectiveness of HDIT-AHSCT and it can be used to expanse the opportunities for providing treatment of patients with MS in the Russian Federation.
- 23 November 2022
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 27 (5) , 25-35
Open AccessHigh-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: preliminary clinical results of approbation of the method
Introduction. In 2018–2020, a study was conducted in the Russian Federation on the efficacy and safety of highdose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT-AHSCT) in multiple sclerosis (MS).The aim of the study was to analyze preliminary data on the effectiveness and safety of the HDIT-AHSCT in patients with MS who participated in the clinical approbation of the method.Material and methods. 21 patients were included in a single-center Pavlov University (Saint Petersburg) observational study. In 10 patients (47.6%) the Expanded Disability Status Scale (EDSS) ranged from 1.0 to 4.0, in 10 — from 4.5 to 6.0 points, 1 patient with primary-progressive MS (PPMS) had 6.5 EDSS points. Cyclophosphamide conditioning regimen (200 mg/kg) in combination with rituximab (1000 mg/m2) was used. Neurological assessment (EDSS, SNRS, T25-FW, 9-HPT, PASAT, MoCA, HADS) and brain MRI were performed before and after 12 months. The early and long-term complications of HDIT-AHSCT were also analyzed.Results. One year after HDIT-AHSCT improvement and significant improvement were noted in 10 patients (47.6%), stabilization — in 8 (38.1%), relapse/progression — in 3 (14.3%). A lower effect was observed in patients with spasticity of more than 3 points by the MAS. According to MRI data 18 patients (85.7%) had stabilization of MS with no disease activity after 1 year, that met the No Evidence of Disease Activity (NEDA) criteria. Long-term complications included autoimmune thyroiditis (n = 1) and amenorrhea in two patients older than 38 years. No TRM were registered during the observation period.Conclusion. HDIT-AHSCT is an effective method of treating patients with multiple sclerosis. The results of the research demonstrate the safety and effectiveness of HDIT-AHSCT and it can be used to expanse the opportunities for providing treatment of patients with MS in the Russian Federation.
- 13 June 2021
- Published by Springer Nature
- p. 552-558
VR Application for Vestibular System Training (Pilot Study)
- 13 June 2021
- Published by Springer Nature
- p. 552-558
VR Application for Vestibular System Training (Pilot Study)